Debut is dipping its toes into the contract manufacturing business, with the goal of bringing biotech ingredients to the masses.The new business division harnesses end-to-end services, including novel ingredient discovery, pre-clinical testing, formulation development, quality control production, and access to Debut’s IP portfolio consisting of more than 7,000 proprietary claims.
Britton estimated that the division will generate net revenue of $100 million in the next five years. If approved, Debut can receive a follow-on award of up to $100 million to build a U.S.-based bio-industrial manufacturing facility.
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Fuente: Investingcom - 🏆 450. / 53 Leer más »